Humulin M3 (30/70) (Insulin Human (Rdna))

Humulin M3 (30/70) is indicated for the control of blood glucose in adults with diabetes mellitus.

• Type 1 diabetes mellitus requiring basal and prandial insulin coverage.
• Type 2 diabetes mellitus when oral agents and lifestyle measures are insufficient.
• Patients who benefit from a fixed ratio of rapid‑acting and intermediate‑acting insulin.
• Use in combination with dietary management and exercise to achieve target glycemic levels.

• Humulin M3 (30/70) contains human insulin that binds to insulin receptors on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling pathways that promote translocation of glucose transporter‑4 (GLUT‑4) to the cell surface, enhancing glucose uptake in muscle and adipose tissue, and suppresses hepatic gluconeogenesis, thereby reducing circulating blood glucose concentrations.

Adverse reactions to Humulin M3 (30/70) may vary in frequency and severity.

Common

• Hypoglycemia, especially if meals are missed or delayed.
• Injection‑site pain, redness, or swelling.
• Weight gain associated with improved glycemic control.
• Lipodystrophy at repeated injection sites.
• Mild edema.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Hypokalemia secondary to rapid glucose shifts.
• Insulin‑induced edema that may exacerbate heart failure.
• Rare cases of insulin antibody formation causing unpredictable glucose control.

When prescribing Humulin M3 (30/70), clinicians should consider several safety factors.

• Assess risk of hypoglycemia and educate patients on recognizing symptoms.
• Adjust doses during illness, reduced food intake, or increased physical activity.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Pregnancy category is unknown; weigh potential benefits against risks.
• Monitor blood glucose regularly to avoid over‑correction.
• Avoid use in individuals with known hypersensitivity to human insulin or any excipients.
• Evaluate cardiovascular status, especially in patients prone to fluid retention.

Humulin M3 (30/70) can interact with other medicines that affect glucose metabolism or mask hypoglycemia.

Avoid

• Concomitant use of other insulin products or high‑dose sulfonylureas, which may precipitate severe hypoglycemia.
• Beta‑adrenergic blockers that can blunt typical hypoglycemia warning signs.
• High‑dose glucocorticoids, which antagonize insulin’s glucose‑lowering effect.
• Thiazide diuretics that may increase blood glucose levels.
• Alcohol excess, which can cause delayed hypoglycemia.

Use with caution

• Oral antidiabetic agents (e.g., metformin, DPP‑4 inhibitors) – monitor glucose closely.
• ACE inhibitors or ARBs – may enhance insulin sensitivity.
• Exercise – adjust insulin dose to prevent hypoglycemia.
• Pregnancy – limited data; monitor maternal and fetal glucose closely.
• Elderly patients – increased sensitivity to insulin, requiring lower doses.